52results about How to "Good antidepressant activity" patented technology

The invention relates to the novel use of pharmaceutical preparations in the field of pharmacy, more specifically the use of barrenwort flavones and barrenwort glycosides monomers as active components in preparing medicament for preventing and treating suppression. Pharmaceutical test shows that, the barrenwort flavones and barrenwort glycosides monomer can appreciably shorten rat's tail suspension time and forced swimming standby time, reverse the decrease of mouse sucrose consumption caused by CMS, suppress animal brain monoamines oxidation enzyme an and B, thus achieving the purpose of suppression resistance.

The invention relates to a new use of 20(S)-protopanoxadiol derivatives and 20(S)-protopanaxatriol derivatives, and mainly relates to a use in the preparation of medicines for treating or preventing depressive mental diseases. 20(S)-protopanoxadiol and 20(S)-protopanaxatriol are used as raw materials, and undergo oxidative cyclization to prepare dammara-20S-24(R)-epoxy-3beta,12beta,25-triol, dammara-20S-24(S)-epoxy-3beta,12beta,25-triol, dammara-20S-24(S)-epoxy-3beta,6beta,12beta,25-tetrol or dammara-20S-24(R)-epoxy-3beta,6beta,12beta,25-tetrol. Researches of pharmacological experiments show that dammara-20S-24(R/S)-epoxy-3beta,12beta,25-triol and dammara-20S-24(R/S)-epoxy-3beta,6beta,12beta,25-tetrol can obviously shorten the tail immobility time of mice in mouse tail suspension tests of a classic depression model, and can obviously shorten the swimming immobility time of the mice in mouse forced swimming model tests, so dammara-20S-24(R/S)-epoxy-3beta,12beta,25-triol and dammara-20S-24(R/S)-epoxy-3beta,6beta,12beta,25-tetraol have potential development values in the preparation of medicines for treating or preventing depressive mental diseases.

The invention discloses a medicine composition for treating depression. The medicine composition consists of the following four components: geniposide, naringin, neohesperidin and magnolol; the medicine composition comprises the following components in parts by weight: 5-20 weight parts of geniposide, 5-20 weight parts of naringin, 5-20 weight parts of neohesperidin and 0.5-2 weight parts of magnolol; and preferably, the medicine composition comprises the following components in parts by weight: 10 weight parts of geniposide, 10 weight parts of naringin, 10 weight parts of neohesperidin and 1 weight part of magnolol. The composition disclosed by the invention can be used for preparing medicines for treating depression, and has the advantages of accurate composition, significant medicine effect, safety and reliability.

The invention discloses rubus parvifolius fractional polysaccharide, a preparation method and an application of the rubus parvifolius fractional polysaccharide in depression resistance. The inventionprovides the fractionated polysaccharide which is extracted and separated from the rubus parvifolius leaves and has the alcohol solubility of 40%-50%, the polysaccharide content is (95.3+/-2.7)%, andthe purity is high; it is found that the rubus parvifolius fractional polysaccharide can remarkably shorten the tail suspension immobility time and the swimming immobility time in a mouse tail suspension test and a mouse forced swimming test, plays a role similar to that of a positive drug, and has obvious anti-depression activity. The rubus parvifolius polysaccharide provided by the invention isa natural active polysaccharide and has no toxic or side effect.

A composite medicine for treating depression is prepared from pachyman (3.5-14 g) and ginger oil (0.2-3.5g) through proportioning, including ginger oil by beta-cyclodextrin, and mixing. Its advantages are sure curative effect and high safety.

The present invention provides compounds with antidepressant activity and a preparation method thereof. The molecular formula of the compound is C13H17NO2Cl, the molecular weight is 252.5, the meltingpoint is 207 DEG C, and the structural formula is shown in the specification. The preparation method comprises the following steps: adding 3-methyl-4-nitrobenzoic acid and thionyl chloride into a first reaction container, stirring, dissolving and uniformly mixing the mixture, and condensing and refluxing the mixture at the temperature of 80 +/-3 DEG C to obtain acyl chloride A1; dropwise adding the acyl chloride A1, cooled to 0 DEG C, into a second reaction container to obtain an intermediate product A2; dissolving A2 in DMF, and adding the solution into a third reaction container to obtain an intermediate product A3; adding the obtained intermediate product A3 into a fourth reaction container to obtain a crude product, and treating the crude product in a chromatographic column to obtainan intermediate product A4; and adding the obtained intermediate product A4 into a sixth reaction container to obtain a powdery solid A5, which is the compound with the antidepressant activity.

The invention discloses xanthone compounds and their use in depression resistance. The xanthone compounds are compounds shown in the structural formula (I) or their pharmaceutically acceptable salts. An experiment proves that the xanthone compounds have good depression-resistant activity and a part of the xanthone compounds have depression-resistant activity superior to that of venlafaxine. Therefore, the xanthone compounds and their pharmaceutically acceptable salts can be used for preparation of depression-resistant drugs.

The invention discloses an application of gecko or extract thereof in preparation of an antidepressant drug. The gecko is the dried body obtained by removing internal organs of Gekko gecko Linnaeus, and the gecko extract is ethanol extract of the gecko. An extraction method of the gecko extract comprises the following steps of taking the gecko, adding ethanol, performing soaking for 40-80 minutes,performing heating, carrying out reflux extraction for 40-80 minutes, performing filtration, repeatedly carrying out reflux extraction on filter residues for multiple times, finally combining filtrates obtained by multiple times of extraction, performing concentration, and recovering the ethanol to obtain the gecko extract. It is found for the first time that the gecko or the extract thereof hasobvious anti-depression activity and has the patent medicine potential of preparing a medicinal preparation for preventing or treating depression and related diseases, and the preparation method of the medicinal preparation is simple, low in cost and good in patent medicine economic benefit.

Belonging to the technical field of traditional Chinese medicines and natural drugs, the invention specifically relates to a Chinese medicinal composition, a preparation method and application thereof. The Chinese medicinal composition is characterized by being prepared from the following Chinese herbal medicines by weight: 10-40 parts of poria, 10-40 parts of pinellia ternata, 10-40 parts of radix bupleuri, 10-40 parts of Fructus aurantii Immaturus, 10-40 parts of Radix Paeoniae Alba, 10-40 parts of Magnolia officinalis, 6-24 parts of licorice, 10-40 parts of gardenia, and 10-40 parts of perilla leaf. The Chinese medicinal composition provided by the invention can be prepared into clinically suitable oral preparations according to traditional Chinese medicine conventional preparation methods. The Chinese medicinal composition significantly shortens the immobility time of mouse tail suspension and forced swimming, significantly increases the hand shaking time of mice given 5-hydroxytryptophan, has a significant antagonistic effect on mouse blepharoptosis and hypothermia caused by reserpine, and significantly antagonizes mouse body temperature decline caused by high dose apomorphine. According to the invention, research results show that the Chinese medicinal composition has a significant anti-mouse experimental depression effect.

A single chiral compound with antidepressant activity and a preparation method and application thereof are related to the technical field of pharmaceutical chemicals. The single chiral compound has a following structural formula. The structure of the compound is different from that of an existing antidepressant compound, and the compound has a novel molecular structure and has good antidepressant activity.